Featured Research

from universities, journals, and other organizations

Cervical Cancer Vaccine Proves Effective: Test Results

Date:
October 12, 2005
Source:
University of Queensland
Summary:
Final-stage clinical trials of a cervical cancer vaccine developed by University of Queensland (UQ) scientists, have shown the drug to be 100 percent effective.

Pioneering research by Professor Ian Frazer from UQ's Centre for Immunology and Cancer Research led to the development of the vaccine.
Credit: Image courtesy of University of Queensland

Final-stage clinical trials of a cervical cancer vaccinedeveloped by University of Queensland (UQ) scientists, have shown thedrug to be 100 per cent effective.

Related Articles


The results of the Phase IIItrials were announced overnight in New York by internationalpharmaceutical company Merck & Co. who are developing the product.

Itwas the pioneering research work of Professor Ian Frazer from UQ'sCentre for Immunology and Cancer Research (CICR) that led to thedevelopment of the vaccine.

Professor Frazer said he was delighted by the news and pleased to have been involved in the vaccine's creation.

“Itis very rare, almost unheard of, to achieve a 100% efficacy rate in anytreatment, so these results are truly wonderful,” he said.

“It isthe first time in the world that a vaccine designed to prevent cancerhas been developed, and it has happened right here in Australia.

“Itis very encouraging to see such great results coming out of Australianresearch, and developed in conjunction with Australian company CSL, andinternational pharmaceutical company Merck & Co.

“It is sad that Dr Jian Zhou, who was my research partner, passed away before the work was publicly recognised.”

Thevaccine is called Gardasil™ and it is expected to be submitted forapproval by the United States Food and Drug Administration (FDA) withinthe next two months.

If the drug is approved by the FDA asanticipated by the international scientific community, the vaccineshould be commercially available in early 2006.

The trial is partof the ongoing phase III program for Gardasil™, which has involved morethan 25,000 people in 33 countries worldwide in total.

Women aged16 years to 26 years were chosen at random to receive a three-doseregimen of either Gardasil™ or placebo at Day 1, Month 2, and Month 6.

Gardasil™was successful in preventing 100 per cent of cases of high-gradepre-cancer and non-invasive cancer associated with human papillomavirus(HPV) strains Type 16 and 18, which cause cervical cancer.

These clinical trial results mirror the outcomes of earlier stage tests also carried out by Merck & Co.

Noneof the women involved in the trial were forced to pull out as a resultof adverse side-affects. The most serious adverse side-affect reportedwas local discomfort at the injection site.

Cervical cancer is one of the few human cancers that is known to be directly caused by a viral infection.

HPVstrain types 16 and 18 lead to the development of cervical cancer, adisease that is the second leading cause of cancer amongst women.

More than 500,000 cases are diagnosed annually and it kills an estimated 275,000 women around the world every year.

Othertypes of the HPV virus cause genital and skin warts. The HPV`s thatconvey a high risk of cervical cancer are contracted by up to anestimated 70 per cent of sexually active women.

Professor Frazersaid Gardasil™ would only protect women who were not infected with HPV,but he hoped to change this in the future.

“My major focus thesedays, as indeed it was right back in the beginning, is on developing avaccine to treat these existing infections,” he said.

“We have produced a second vaccine which we hope will do this, however clinical trials are still at a very early stage.

“A therapeutic vaccine to treat already infected individuals is much harder to develop than a vaccine to prevent infection.”

ProfessorFrazer hails from Scotland and trained as a renal physician andclinical immunologist in Edinburgh before immigrating to Australia in1980.

In addition to his responsibilities as Head of CICR, he isthe director of a biotechnology start up company, Coridon, which has aninterest in optimising and targeting polynucle vaccine proteinexpression.


Story Source:

The above story is based on materials provided by University of Queensland. Note: Materials may be edited for content and length.


Cite This Page:

University of Queensland. "Cervical Cancer Vaccine Proves Effective: Test Results." ScienceDaily. ScienceDaily, 12 October 2005. <www.sciencedaily.com/releases/2005/10/051011065519.htm>.
University of Queensland. (2005, October 12). Cervical Cancer Vaccine Proves Effective: Test Results. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2005/10/051011065519.htm
University of Queensland. "Cervical Cancer Vaccine Proves Effective: Test Results." ScienceDaily. www.sciencedaily.com/releases/2005/10/051011065519.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins